Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over study of continued darolutamide treatment in prior Bayer darolutamide trial participants
2022-502084-38-00Phase 3Authorised
- Sponsor
- Bayer Consumer Health
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 37
01
Overview
Phase 3, open-label, single-arm trial of darolutamide in prostate cancer (PCa), sponsored by Bayer Consumer Health. Primary endpoints: Incidence of TEAEs, Incidence of TESAEs and 1 more. Planned start Oct 2020; status: authorised.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-502084-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502084-38-00.